5/30
09:30 am
kymr
Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference [Yahoo! Finance]
Low
Report
Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference [Yahoo! Finance]
5/30
09:25 am
kymr
Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference [Financial Post (Toronto, Ontario, Canada)]
5/29
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
Medium
Report
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
5/24
08:04 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
5/23
05:03 pm
kymr
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting [Yahoo! Finance]
5/23
05:00 pm
kymr
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Low
Report
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
5/22
11:25 am
kymr
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting [Yahoo! Finance]
5/22
11:20 am
kymr
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
Low
Report
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
5/14
10:06 am
kymr
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting [Yahoo! Finance]
5/14
10:00 am
kymr
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Medium
Report
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
5/8
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
5/5
08:42 am
kymr
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think [Yahoo! Finance]
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think [Yahoo! Finance]
5/3
12:29 pm
kymr
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/3
11:53 am
kymr
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]
Low
Report
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]
5/3
11:53 am
kymr
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know [Yahoo! Finance]
5/3
09:57 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $53.00 to $52.00. They now have an "outperform" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $53.00 to $52.00. They now have an "outperform" rating on the stock.
5/2
07:00 am
kymr
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
Medium
Report
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
4/25
07:00 am
kymr
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
Medium
Report
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
4/22
08:09 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $53.00 price target on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $53.00 price target on the stock.
4/8
07:18 am
kymr
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting [Yahoo! Finance]
4/8
07:00 am
kymr
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Low
Report
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
3/8
10:14 am
kymr
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]
3/8
10:00 am
kymr
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
Low
Report
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
3/4
11:38 pm
kymr
Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) [Yahoo! Finance]
Low
Report
Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) [Yahoo! Finance]
3/3
07:31 am
kymr
Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher [Yahoo! Finance]
Low
Report
Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher [Yahoo! Finance]